Read our independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Our work is reader-supported. Sign up to our free or paid plans here.
Pα+ Library: we introduce some of the key concepts in the matter of bifurcated scheduling; a process by which an approved drug product may be placed in a different schedule to the substance itself. As we discuss in this piece, this could have significant repercussions for psychedelic research, legality, and even taxes.
GH Research’s Lead 5-MeO-DMT Candidate Faces Development Hiccup • Psychae Therapeutics Scores AUD $4.5m to Develop DMT-Based Candidate • Cybin Closes $30m Offering • Grants Awarded to 8 ‘Young Investigators’ Exploring Psychedelics • atai Buys Out Remainder of DemeRx’s Ibogaine Asset; Announces Novel 5-HT2A Agonist Candidates • Compass Commences UK Portion of Phase 3 Trial, Officially Opens London Centre • Awakn Plans to Commence Enrollment for Phase 3 Study of Ketamine for Severe Alcohol Use Disorder in Q1 2024 • 14% of travellers are interested in a psychedelic retreat in 2024
This month: MindMed scores psilocybin-antidepressant co-treatment patent • A spate of PCTs published from GH Research • Early fruits of Cybin’s Small Pharma acquisition • and more…
We spoke to Ester Kincová and Steve Rolles from Transform Policy Foundation, co-authors of a new publication, ‘How to Regulate Psychedelics’. We sought to better understand their perspectives on emergent international psychedelic policy ‘experiments’ and broader contexts.
Earlier this month Eddie Jacobs et al. published an article in Neuroethics titled, When the Trial Ends: The Case for Post-Trial Provisions in Clinical Psychedelic Research. We asked Jacobs a few questions about the current and potential state of post-clinical-trial support.
TREAT Retreats • Wiener Regroups: Decrim. Off the Agenda • California Psilocybin Decrim. Initiative Continues Signature Gathering • Veterans’ Affairs Subcommittee on Health Discusses Psychedelics • Canadian Senate Subcommittee on Veterans Affairs: “The Time is Now” to Fund Psychedelic Research • Transform Publishes “Practical Guide” to Regulating Psychedelics • UK Government Responds to Drugs Committee’s Report • Other Policy-Related News
Through our years of reporting we have covered many of the topics we believe to be important to the present and future of the psychedelics space, broadly defined. However, much of this commentary is scattered across Bulletins, deep dives, special reports and year-end reviews.
The Library provides digestible explainers on salient topics across psychedelic drug development, policy and business: from basic explainers such as “what is psychedelic-assisted therapy?” through to more complex matters such as REMS programs and bifurcated scheduling.
It’s exclusively available to our Pα+ subscribers, with new content added regularly.
Pα+ Library: we introduce some of the key concepts in the matter of bifurcated scheduling; a process by which an approved drug product may be placed in a different schedule to the substance itself. As we discuss in this piece, this could have significant repercussions for psychedelic research, legality, and even taxes.
Pα+ Library: we sketch out what a psychedelic REMS might look like, highlighting how these programs could have an outsized impact on the post-approval delivery and accessibility of these treatments.
Archived versions of our Psychedelic News Feed.
This is an archived version of our Psychedelic News Feed, from October 9 – November 5, 2023.
Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond
Insights and interviews delivered to your inbox. No spam, just valuable information.
